Intraocular lens

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Retrieved on: 
Wednesday, March 6, 2024

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide.

Key Points: 
  • Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide.
  • Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe.
  • Vivity is available in more than 80 countries, including Australia, Brazil, Canada, China, France, Germany, Japan, India, Italy, South Korea, Spain, U.K. and U.S. Alcon offers a family of leading IOLs designed to meet the unique vision needs of patients, including Vivity and PanOptix®—the most implanted PCIOLs worldwide—as well as Monofocal and Toric options.
  • PanOptix surpassed 1M implants in early 2022, and is the most implanted trifocal worldwide.5,6 For more information, please visit www.alcon.ca .

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Retrieved on: 
Wednesday, March 6, 2024

Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.

Key Points: 
  • Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.
  • Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe.
  • The Vivity Registry Study4+ includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy, as well as post-refractive eyes.
  • PanOptix surpassed one million implants in early 2022, and is the most implanted trifocal worldwide.5,6 For more information, please visit www.ClareonIOL.com .

New Swiss Made Features for Cataract Surgery Lens Selection

Retrieved on: 
Thursday, February 22, 2024

The company Swiss Advanced Vision (SAV-IOL SA) has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.

Key Points: 
  • The company Swiss Advanced Vision (SAV-IOL SA) has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.
  • View the full release here: https://www.businesswire.com/news/home/20240222791326/en/
    Launch of New Features, discover the unique Incision Location Optimization tool on SAV-IOL Toric Calculator.
  • Since 2009, the Swiss company has been developing advanced IOLs with the goal to restore the missing accommodation left by the removal of the natural lens.
  • Swiss Advanced Vision will keep the pace of innovative product development and is already working on new functionalities for their users, stay tuned!

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Retrieved on: 
Wednesday, February 21, 2024

For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.

Key Points: 
  • For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the fourth quarter of 2023 was $0.24, as compared to $0.23 for the fourth quarter of 2022.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the full year of 2023 was $0.73, as compared to $1.07 for the full year of 2022.
  • Bausch + Lomb provided guidance for the full year of 2024, as follows.

SIFI ANNOUNCES THE ESTABLISHMENT OF A JOINT VENTURE IN THE UNITED ARAB EMIRATES

Retrieved on: 
Monday, February 5, 2024

The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.

Key Points: 
  • The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.
  • The JV will be based in Dubai and initially focus on the United Arab Emirates ("UAE"), expanding its commercial reach to Bahrein, Oman, Qatar, Kuwait, and the Kingdom of Saudi Arabia as a second step.
  • Approximately 100.000 cataract surgeries are performed each year across these Countries with an annual growth rate of 3.0%, with almost 50% Premium IOLs.
  • "It is therefore a great honor to invest alongside SIFI and bring such innovation to ophthalmologists and patients".

SIFI ANNOUNCES THE ESTABLISHMENT OF A JOINT VENTURE IN THE UNITED ARAB EMIRATES

Retrieved on: 
Monday, February 5, 2024

The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.

Key Points: 
  • The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.
  • The JV will be based in Dubai and initially focus on the United Arab Emirates ("UAE"), expanding its commercial reach to Bahrein, Oman, Qatar, Kuwait, and the Kingdom of Saudi Arabia as a second step.
  • Approximately 100.000 cataract surgeries are performed each year across these Countries with an annual growth rate of 3.0%, with almost 50% Premium IOLs.
  • "It is therefore a great honor to invest alongside SIFI and bring such innovation to ophthalmologists and patients".

Intraocular Lens (IOL) Developmental Pipeline: 2023 Update Unveils Industry Progress with Global Insights - Collaborative and Regulatory Landscapes and Clinical Trials and Market Strategies - ResearchAndMarkets.com

Retrieved on: 
Monday, January 29, 2024

The medical devices sector has observed a significant surge in the developmental pipeline of Intraocular Lens (IOL) products.

Key Points: 
  • The medical devices sector has observed a significant surge in the developmental pipeline of Intraocular Lens (IOL) products.
  • A recent report provides a thorough analysis of advancements that mark critical progress in eye care technology across various stages of development.
  • The comprehensive coverage offers a deeper understanding of the upcoming innovations and their expected impact on the eye care industry at a global level.
  • The groundbreaking report systematically categorizes the developments in the IOL pipeline, providing an insightful review of major products in progress.

NVISION Continues Expansion in Texas with Parkhurst NuVision Joint Venture

Retrieved on: 
Thursday, January 18, 2024

NVISION Eye Centers, a national leader in eye care services, is proud to announce its continued expansion in Texas with a new Joint Venture partnership with Parkhurst NuVision in San Antonio and New Braunfels.

Key Points: 
  • NVISION Eye Centers, a national leader in eye care services, is proud to announce its continued expansion in Texas with a new Joint Venture partnership with Parkhurst NuVision in San Antonio and New Braunfels.
  • Parkhurst NuVision (PNV) was founded in 2013 by Dr. Gregory Parkhurst.
  • NVision’s unique Joint Venture model is very different from private equity funds because at its core lies physician leadership along with substantial equity and influence.
  • “We are thrilled to partner with Dr. Parkhurst and the Parkhurst NuVision team,” said Chris Karkenny, CEO of NVISION.

Dr. George Waring, IV Agrees to Serve as the Chairman of the Trusted LASIK Surgeons™ Advisory Board

Retrieved on: 
Monday, December 11, 2023

CHARLESON, S.C., Dec. 11, 2023 /PRNewswire-PRWeb/ -- Trusted LASIK Surgeons™- Charleston, SC - December 11, 2023. Trusted LASIK Surgeons™, the premier LASIK, cataract and refractive surgeon directory service, is pleased to announce that Charleston LASIK Surgeon, Dr. George O. Waring, IV, MD, FACS, founder of the Waring Vision Institute, has agreed to serve as the Chairman of its advisory board. Dr. Waring is trusted by the ophthalmology community as one of the top experts in all types of laser vision correction, cataract and refractive surgery, including LASIK, premium lens implants (IOLs), EVO-ICLs and corneal inlay procedures.

Key Points: 
  • Trusted LASIK Surgeons™ is pleased to announce Dr. George O. Waring, IV, of the Waring Vision Institute, as the Chairman of its advisory board.
  • Trusted LASIK Surgeons™, the premier LASIK, cataract and refractive surgeon directory service, is pleased to announce that Charleston LASIK Surgeon , Dr. George O. Waring, IV, MD, FACS , founder of the Waring Vision Institute, has agreed to serve as the Chairman of its advisory board.
  • As Chairman of the Trusted LASIK Surgeons™ advisory board, Dr. Waring will help ensure that the quality of content on our website meets the high standards first set by Dr. James J. Salz, the co-founder of Trusted LASIK Surgeons™, who passed away in March 2022.
  • As a result, Trusted LASIK Surgeons™ brings patients together with the top refractive surgeons in the discipline."

STAAR Surgical Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 1, 2023

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 29, 2023.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 29, 2023.
  • Other Product sales for the third quarter of 2023 were ($0.8) million compared to $4.1 million in the prior year quarter.
  • Gross profit margin for the third quarter of 2023 was 79.2% compared to the prior year quarter of 79.5%.
  • Operating expenses for the third quarter of 2023 were $57.3 million compared to the prior year quarter of $46.8 million.